Experimental gerontologySep 14, 2026

GLP-1 receptor drugs, aging-related gene changes, and possible lifespan extension with medicine

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 15, 2026

Abstract

A 19% reduction in all-cause mortality was observed in patients with obesity without diabetes using glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

GLP-1 RAs have been associated with reduced major adverse cardiovascular events and systemic inflammation.
The SELECT trial showed a hazard ratio of 0.81 for all-cause mortality in treated patients.
The FLOW trial reported a 24% reduction in the primary kidney composite endpoint with a hazard ratio of 0.76.
Significant deceleration of validated DNA methylation clocks was observed after 32 weeks of semaglutide therapy.
Convergent pathways involving the hypothalamic GLP-1 receptor and AMPK/SIRT1 signaling may play a role in the effects of GLP-1 RAs.
Further studies are needed to establish definitive evidence, including trials with diverse populations and prespecified endpoints.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events, all-cause mortality, and systemic inflammation in randomized controlled trials, with effect sizes exceeding those predicted from glycemic and weight-related improvements alone. The convergence of these findings with a maturing body of evidence linking metabolic dysfunction to accelerated epigenetic aging has prompted renewed interest in GLP-1 RAs as candidate gerotherapeutic agents. The present review synthesizes contemporary preclinical, mechanistic, and clinical evidence relevant to this question. The SELECT trial demonstrated a 19% reduction in all-cause mortality (hazard ratio [HR] 0.81) in patients with obesity without diabetes, the FLOW trial demonstrated a 24% reduction in the primary kidney composite endpoint (HR 0.76), and the first randomized evidence of GLP-1 RA modulation of validated DNA methylation clocks was reported in 2025, with significant deceleration of DunedinPACE, PCGrimAge, and PhenoAge over 32 weeks of semaglutide therapy. Mechanistic studies have identified convergent pathways involving the hypothalamic GLP-1 receptor, AMPK/SIRT1 signaling, and microbiome-derived short-chain fatty acid production. The aggregate evidence supports the framing of GLP-1 RAs as a candidate class of geroprotective therapeutics, although definitive trials with prespecified epigenetic aging endpoints, durability follow-up, body-composition assessment, prespecified sex-stratified analyses, and adequate representation of diverse populations remain to be conducted; the pending EVOKE and EVOKE+ readouts in early Alzheimer's disease will be particularly consequential.

Full Text

Full text is available at the source.

View Full Text ↗

GLP-1 receptor drugs, aging-related gene changes, and possible lifespan extension with medicine

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief